ICAM1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL609962	1.00	20/20
SCHEMBL879320	1.00	20/20
SCHEMBL879361	1.00	20/20
SCHEMBL879369	1.00	20/20
SCHEMBL879397	0.78	20/20
SCHEMBL879362	0.77	20/20
SCHEMBL879396	0.77	20/20
SCHEMBL879360	0.76	20/20
SCHEMBL879319	0.76	20/20
SCHEMBL879334	0.69	20/20
SCHEMBL879338	0.69	20/20
SCHEMBL879401	0.63	20/20
SCHEMBL879391	0.57	20/20
SCHEMBL879351	0.57	20/20
SCHEMBL879343	0.56	20/20
SCHEMBL879340	0.53	20/20
SCHEMBL879387	0.52	20/20
SCHEMBL879390	0.52	20/20
SCHEMBL879341	0.52	20/20
SCHEMBL879404	0.52	20/20

Clinical trials — most relevant to ICAM1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Glucose Degradation Products (GDP) on Endothelial Dysfunction	PHASE4	COMPLETED
Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes	PHASE4	COMPLETED
Atorvastatin in Acute Stroke Treatment	PHASE4	COMPLETED
Effects of Anemia Correction on Vascular and Monocyte Function in Renal Transplant Recipients	PHASE4	COMPLETED
Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance.	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease	PHASE2	COMPLETED
PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease	PHASE2	COMPLETED
Defibrotide in COVID-19 Pneumonia	PHASE2	COMPLETED
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation	PHASE2	COMPLETED
Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma	PHASE2	COMPLETED
Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis	PHASE2	COMPLETED
Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)	PHASE2	RECRUITING
A Supervised Nutritional Program in Pregnancies and NF-κB Expression in Placenta	PHASE1	COMPLETED
Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study	PHASE1	WITHDRAWN
A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations	PHASE1	COMPLETED
Comparing The Effect of Tadalafil 5 mg/Day to Sildenafil 25 mg/Day on Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Erectile Dysfunction Patients; and Comparison of Clinical Response	EARLY_PHASE1	UNKNOWN
Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level	nan	COMPLETED
Indoxyl Sulfate Induces Leukocyte-endothelial Interactions Through Up-regulation of ICAM-1 in Acute Kidney Injury	nan	UNKNOWN
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL	nan	COMPLETED
Abdominal Aortic Aneurysm Surgery and Thrombosis	nan	COMPLETED
Von Willebrand Antigen and Activity as Novel Biomarkers of Hemostasis in Inflammatory Bowel Disease	nan	UNKNOWN
Do Omega-3 Fatty Acids Have an Antidepressant Effect in Patients With Signs of Peripheral Inflammation?	nan	COMPLETED
Role of Endothelial Cells in the Pathogenesis of Chronic Urticaria.	nan	UNKNOWN
Microcirculation and Bone Metabolism in Patients With Type 2 Diabetes Mellitus and Charcot Foot - A Pilot Study	nan	COMPLETED
Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock	nan	WITHDRAWN
Endothelial Dysfunction and Selenium Status in Children With Acute Systemic Inflammatory Response	nan	COMPLETED
Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis	nan	ENROLLING_BY_INVITATION
Soluble Receptors for Advanced Glycation End-Products and PCI	nan	UNKNOWN
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches	nan	UNKNOWN
Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a ICAM1 binder may also engage these)

Protein	Name	Similarity
Q5NKV4	—	1.000	Q5NKV4 →
Q5NKV9	—	1.000	Q5NKV9 →
Q28806	—	1.000	Q28806 →
Q28125	—	0.999	Q28125 →
Q5NKV6	—	0.994	Q5NKV6 →
Q95132	—	0.991	Q95132 →
P32942	—	0.991	P32942 →
Q5NKU6	—	0.988	Q5NKU6 →
P33729	—	0.988	P33729 →
Q00238	—	0.987	Q00238 →
P13597	—	0.987	P13597 →
A6JNN4	—	0.979	A6JNN4 →
Q28730	—	0.979	Q28730 →
Q5NKV1	—	0.978	Q5NKV1 →
A6NMB1	—	0.978	A6NMB1 →
P15151	—	0.978	P15151 →
Q60625	—	0.975	Q60625 →
Q9MZ08	—	0.972	Q9MZ08 →
Q14773	—	0.971	Q14773 →
Q9N2I5	—	0.971	Q9N2I5 →
P35330	—	0.971	P35330 →
Q5NKV2	—	0.971	Q5NKV2 →
M3XWH1	—	0.969	M3XWH1 →
P32506	—	0.969	P32506 →
Q80ZE3	—	0.969	Q80ZE3 →
Q9WUL5	—	0.968	Q9WUL5 →
P13598	—	0.968	P13598 →
Q96LC7	—	0.968	Q96LC7 →
CSF3R	Granulocyte colony-stimulating factor receptor	0.968	landscape →
Q6DN72	—	0.968	Q6DN72 →